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Abstract
To investigate the cellular/molecular basis of the ac-
tivity of a novel lipophilic camptothecin, gimatecan
(ST1481), against slowly proliferating cells, we per-
formed a comparative study of topotecan and gimate-
can in human bladder cancer models (HT1376 and
MCR). Gimatecan was significantly more effective than
topotecan in inhibiting the growth of HT1376 tumor,
thus reflecting antiproliferative potency. In both
HT1376 and MCR cells, gimatecan caused a persistent
S-phase arrest, indicating an efficient DNA damage
checkpoint. This response was consistent with a
cytostatic effect, because no evidence of apoptosis
was detected. In contrast to gimatecan, topotecan at
equitoxic concentrations caused an early and persis-
tent downregulation of topoisomerase I. Modulation
of protein level could not be solely ascribed to the
proteasome-mediated degradation of the enzyme be-
cause the proteasome inhibitor PS341 sensitized
MCR but not HT1376 cells to camptothecins, suggest-
ing alternative mechanisms of drug-induced topo-
isomerase I downregulation. Indeed, the two
camptothecins caused a differential inhibition of
topoisomerase I transcription, which is more marked
in topotecan-treated cells. The HT1376 model was
more sensitive to this immediate decrease of mRNA
level. Our data document a marked antitumor activity
of gimatecan against a bladder carcinoma model. A
limited downregulation of topoisomerase I by gimate-
can provides additional insights into the cellular
basis of drug potency.
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Introduction
Camptothecins are among the most promising antitumor
agents [1,2]. On the basis of their therapeutic interest,
intense research efforts have provided insights to under-
stand their mechanism of action and to exploit their anti-
tumor potential [3,4]. Camptothecins are DNA-damaging
agents characterized by a unique mechanism of action be-
cause they are target-specific inhibitors of DNA topoisomerase
I by stabilizing the covalent enzyme–DNA complex (cleavable
complex) [5,6].
Due to the specific mechanism of topoisomerase I–medi-
ated cytotoxicity, a characteristic feature of camptothecin ac-
tion is their preferential or selective toxicity to proliferating cells
[7]. Indeed, these agents are considered S-phase–specific
because the lethal DNA lesions are formed during DNA syn-
thesis as a consequence of collision between the replication
machinery and the enzyme–DNA-cleavable complex [6]. For
this reason, tumors with a high fraction of proliferating cells are
expected to be more responsive to camptothecins than slowly
growing tumors.
We have recently reported that slowly proliferating cells are
still sensitive to a novel potent camptothecin analogue, gima-
tecan (ST1481) [8]. The molecular/cellular basis of this unique
feature remains unknown. To elucidate the molecular events
responsible for the potency and efficacy of gimatecan against
slowly growing tumor cells, we have chosen two bladder
carcinoma cell systems. The results of cellular pharmacology
and antitumor activity studies support the therapeutic potential
of the novel camptothecin against bladder carcinoma and
provide additional insights on the molecular events responsible
for its antiproliferative and antitumor potency.
Materials and Methods
Cell Lines
The study was performed on two human bladder carcinoma
cell lines, including HT1376 and MCR (established in our
laboratory), characterized by similar doubling times (38 and
42 hours, respectively). HT1376 cells are known to harbor
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a p53 mutation, whereas the MCR cells, characterized in
our laboratory, harbor two p53 mutations: one in exon 4
(CGC!CCC) and one in exon 9 (CAG!TAG), with the latter
producing a stop codon that determines a truncated protein
form. Cells were maintained as a monolayer in culture
medium (DMEM) supplemented with 10% fetal calf serum,
100 U/ml penicillin, 100 mg/ml streptomycin, and 2 mM
L-glutamine, and were subcultured weekly. All experiments
were performed during exponential cell growth.
Drugs
ST1481 (t-butoxyiminomethylcamptothecin, gimatecan;
Sigma-Tau, Pomezia, Rome, Italy) was dissolved in dime-
thylsulfoxide (DMSO) and stored at 20jC until use.
Immediately before treatment, ST1481 and topotecan
(Glaxo-SmithKline, Brentford, UK) were diluted in culture
medium. Because the molecular weights of topotecan and
gimatecan were similar (457.96 and 447.5, respectively),
the concentrations were usually expressed in micrograms
per milliliter, or nanograms per milliliter.
Antitumor Activity Studies
Antitumor activity experiments were carried out using
female athymic Swiss nude mice 8 to 10 weeks of age
(Charles River, Calco, Italy). Mice were maintained in lami-
nar flow rooms, keeping temperature and humidity constant.
Mice had free access to food and water. Experiments were
approved by the Ethics Committee for Animal Experimenta-
tion of the Istituto Nazionale Tumori (Milan, Italy).
Tumor lines were established in vivo by subcutaneous
injection of 107 cells from in vitro cultures. Randomized
groups of five mice bearing bilateral subcutaneous tumors
were used. The mean tumor doubling time in control mice
was 8.6 days. The drugs were delivered by gavage in a
volume of 10 ml/kg body weight every fourth day for four
times (q4  d  4) at their maximum tolerated doses start-
ing when tumors were measurable (around 50 mg). For
statistical analysis, tumor volumes of ST1481-treated versus
TPT-treated mice were compared by Student’s t test.
Cell Sensitivity Studies
Cell sensitivity to drugs was measured by growth inhibi-
tion assay after 1, 6, and 24 hours of exposure to ST1481
and 1-hour exposure to topotecan. Cells in the logarithmic
growth phase were seeded in triplicate in 50-mm plates.
Twenty-four hours after seeding, the drug was added to the
medium. Cells were harvested 72 hours after drug exposure
and counted with a cell counter. In independent experiments,
antiproliferative effects of drug treatment were assessed
by the sulforhodamine B (SRB) assay [9]. IC50 is defined
as the drug concentration causing a 50% reduction in cell
number compared to that of untreated control.
The effects of combination of camptothecins with PS341
on cell growth were assessed by SRB assay. Following a
1-hour exposure to camptothecin, cells were incubated for
a further 72 hours with the proteasome inhibitor, PS341.
Drug interaction was examined according to the method of
Drewinko et al. [10], using the following formula:
CI ¼ ðSFa SFbÞ
SFðaþ bÞ =100
where SF indicates the survival fraction observed for each
drug (a and b), or for cotreatment (a + b). The nature of the
interaction is interpreted on the basis of CI values (i.e., CI > 1,
synergism; CI = 1, additivity; CI < 1, antagonism).
Cell cycle perturbation
Control cells and cells exposed to 0.003 and 0.03 mg/ml
gimatecan (ST1481) for 1, 6, or 24 hours followed by a
72-hour incubation in drug-free medium were trypsinized,
washed twice with PBS, fixed in ice-cold ethanol 70%, and
stained in a solution containing RNAase (10 kU/ml; Sigma-
Aldrich, St. Louis, MO), NP40 (0.01%; Sigma-Aldrich), and
propidium iodide (20 mg/ml; Sigma-Aldrich). Samples were
stored for 60 minutes and analyzed by flowcytometry (FACS
Vantage flow cytometer; Becton Dickinson, San Jose, CA).
For each sample, 10,000 events were collected for subse-
quent analysis. Data analysis was performed using CELL
Quest software (Becton Dickinson). Data were elaborated
using Modfit (DNA Modeling System) software (Verity Soft-
ware House, Inc., Topsham, ME) and expressed as fractions
of cells in different cell cycle phases. Samples were run in
triplicate, and each experiment was repeated three times.
Values of treated samples are expressed as a percentage
of controls.
Apoptosis
After a 6-hour exposure to 0.03 mg/ml gimatecan
(ST1481) followed by 12, 24, 48, or 72 hours of incubation
in drug-free medium, cells were trypsinized, washed twice
with PBS, and fixed in 1% paraformaldehyde in PBS on ice
for 15 minutes. After two washes in PBS, cells were resus-
pended in ice-cold 70% ethanol, stored overnight at 20jC,
then washed in PBS and incubated in 50 ml of solution
containing terminal deoxynucleotidyltransferase and FITC-
conjugated dUTP deoxynucleotides (1:1) in reaction buffer
(Boehringer Mannheim, Mannheim, Germany) for 60 min-
utes at 37jC in the dark. After washing in PBS containing
0.1% Triton X-100, cells were stained with 5 mg of propidium
iodide (Sigma-Aldrich) and 10 kU of RNAase (Sigma-Aldrich)
in 1 ml of PBS overnight at 4jC in the dark. Flow cytometric
analysis was performed on a FACS Vantage flow cytometer
(Becton Dickinson). Data acquisition and analysis were
performed using CELLQuest software (Becton Dickinson).
For each sample, 10,000 events were recorded.
Preparation of Nuclear Extract
After 1-hour exposure to ST1481 or topotecan at IC50
concentrations followed by 4, 24, or 72 hours of incubation in
drug-free medium cells, (5  106) were harvested by
trypsinization, washed with PBS, and resuspended in 5 ml
of nuclear buffer [100 mM NaCl, 1 mM KH2PO4, 5 mM
MgCl2, 1 mM EGTA, 10 mM b-Me, 10% (vol/vol) glycerol,
pH 6.4]. After addition of 45 ml of nuclear buffer containing
0.35% (vol/vol) Triton X-100 and 0.5 mM PMSF, the cell
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suspension was kept on ice for 30 minutes and the nuclei,
collected by centrifugation at 1000g for 10 minutes, were
washed once with Triton X-100–free nuclear buffer, then
incubated for 1 hour at 4jC in lysis buffer [100 mM NaCl,
5 mM KH2PO4, 0.5 mM EGTA, 10 mM b-Me, 10% (vol/vol)
glycerol, 10 mM NaHSO3, pH 7.0] containing 0.35 M NaCl in
gentle rotation. The lysate was centrifuged at 12,000g for
15 minutes and the protein concentration was determined
using the BioRad Protein Concentration Assay (Bio-Rad
Laboratories, Hercules, CA). The nuclear protein extract
was immediately assayed for topoisomerase I activity and
Western blot analysis.
Topoisomerase I Activity Assay
The activity of DNA topoisomerase I was determined by
measuring the relaxation of supercoiled pBR322 DNA (Invi-
trogen Corporation, Carlsbad, CA). The reaction mixture
(final volume, 20 ml) containing 20 mM Tris–HCl (pH 8.0),
10 mM MgCl2, 0.1 mM EDTA, 0.5 mg/ml bovine serum
albumin (BSA), 150 mM NaCl, and 0.375 of mg pBR322,
and different dilutions of nuclear extract was incubated at
37jC for 30 minutes. The reaction was stopped by adding
1% sodium dodecyl sulfate (SDS) and 0.3 mg/ml proteinase
K. The samples were loaded on 1% agarose gel in TBE
buffer (0.089 M Tris base, 0.089 M boric acid, and 0.002 M
EDTA) and were run for 6 hours at 40 V. After staining with
0.5 mg/ml ethidium bromide, the gels were photographed
under UV light.
Western Blot Assay
For the determination of topoisomerase I expression,
nuclear protein extracts (3 mg) were fractionated onto 8%
SDS polyacrylamide gel and transferred onto nitrocellulose
membrane. For the analysis of 20S proteasome subunit a2
expression, a total cell lysate (80 mg of protein) was used.
Filters were probed overnight with purified mouse antihuman
DNA topoisomerase I monoclonal antibody (BD PharMingen,
San Diego, CA) or mouse monoclonal antibody against 20S
proteasome subunit a2 (Affiniti, Devon, UK). The mem-
branes were then incubated with horseradish peroxidase–
conjugated secondary antibody (Santa Cruz Biotechnology,
Santa Cruz, CA). A rabbit antiactin antibody was used as
control for loading. Antibody binding to the nitrocellulose
blots was detected by enhanced chemiluminescence (Amer-
sham Pharmacia Biotech Italia, Cologno Monzese, Italy).
Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Analysis of Topoisomerase I Gene
Expression of topoisomerase I gene was analyzed by
RT-PCR. Total cellular RNA was isolated by using a com-
mercially available kit (Talent, Trieste, Italy). Two micro-
grams of RNA was reversed-transcribed into cDNA with the
use of oligo(dt) primers and Moloney murine leukemia virus
reverse transcriptase (Invitrogen Corporation). To amplify
the topoisomerase I transcript, the 5V-atgagtggggaccacctc-
cacaa-3V/5V-ttcattagtcatttcctttctccagt-3Vprimers were used.
The amplified fragment was 866 bp. PCR conditions were
as follows: 95jC, 9 minutes for one cycle; 95jC, 1 minute,
52jC, 1 minute, 72jC, 1 minute for 30 cycles followed by
10-minute extension at 72jC. In the case of b-actin, which
was used as a control (actin primers: 5V-gaaactaccttcaactc-
catc-3V and 5V-ggcggctccatcctggcctcg-3V), the annealing tem-
perature was 62jC and the amplified product was 300 bp.
The amplification products were separated on a 1.5% aga-
rose gel containing ethidium bromide and UV-visualized
by using a VDS Image Master (Amersham Pharmacia
Biotech Italy). The amplified products were quantified by
Imagequant program.
Results
Antitumor Activity Studies
The antitumor activity of the two camptothecins, gimate-
can (ST1481) and topotecan, was investigated only in the
model HT1376 growing subcutaneously in athymic Swiss
nude mice because the MCR cells were tumorigenic in not all
mice (Figure 1). This comparative study was performed with
Table 1. Cellular Sensitivity to Gimatecan (ST1481) and Topotecan.
Drug Exposure Time IC50 (ng/ml)*
MCR HT1376
Topotecan 1 900 ± 40 800 ± 20
ST1481 1 90 ± 3 9.0 ± 0.4
1y 81 ± 20y 20 ± 9y
24 5.0 ± 0.2 2.8 ± 0.1
*IC50 values were calculated from the dose– response curve.
yCells were exposed to the drug for the indicated times and the
antiproliferative effects were determined after incubation in drug-free medium
for 72 hours, with the cell counting method or SRB method.
Figure 1. Antitumor activity of topotecan and gimatecan against the human
bladder carcinoma xenograft. Treatment per os, every fourth day for four
times. Arrows indicated the days of treatment.
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the schedule q4d  4, using optimal doses of each agent
(i.e., maximum tolerated doses), chosen on the basis of
previous studies [11]. Topotecan exhibited only a moderate
efficacy at the optimal oral dose of 15 mg/kg. Using the same
schedule, the optimal dose of gimatecan (2 mg/kg) was
substantially more effective, causing a marked tumor growth
inhibition during treatment. The antitumor effects of the two
camptothecins were significantly different (P < .01, 1 week
after the end of treatment). The increased inhibition of tumor
growth by gimatecan was also reflected in log cell kill values
(0.6 vs 1.6, for topotecan versus gimatecan).
Cellular Sensitivity Studies
Table 1 shows the antiproliferative activity of gimatecan
determined after different exposure times. Dose–response
curves in the range of 3 to 300 ng/ml (not shown) and IC50
values (Table 1) indicated that the growth-inhibitory effect of
Figure 2. Cell cycle analysis of HT1376 andMCRcells after exposure to gimatecan (ST1481). Cells were exposed to 0.003 g/ml (approximately IC50) and 0.03 g/ml
(approximately IC80) of ST1481 for 24 hours and processed for cytofluorimetric analysis after 72-hour incubation in drug-free medium. (A and D) Untreated control.
(B and E) Cells treated with 0.003 g/ml. (C and F) Cells treated with 0.03 g/ml.
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the drug was dose-dependent and time-dependent. HT1376
cells were more sensitive than MCR cells at least following a
short-term exposure. The marginal difference in growth rate
did not account for the differential sensitivity. The antiproli-
ferative potency of the drug was substantially higher than
that of topotecan used as a reference compound in both cell
lines (Table 1). This finding was consistent with the in-
creased antitumor activity of gimatecan.
Cell Cycle Analysis and Apoptosis
The effects of gimatecan (ST1481) on cell cycle progres-
sion were examined in cells treated for 24 hours at two
drug levels in the range of antiproliferative concentrations,
and then incubated in drug-free medium for 72 hours. At
0.003 mg/ml (approximately IC50), a substantial fraction of
cells was found in S-phase, and the number of S-phase
cells increased after treatment with a higher concentration
(0.03 mg/ml; i.e., IC80) (Figure 2). The cytofluorimetric analy-
sis of TUNEL-positive cells revealed no appreciable amount
of apoptotic cells in both cell lines at 72 hours after a 6-hour
exposure to 0.03 mg/ml ST1481 (not shown).
Effect on Topoisomerase I Activity and Expression
The effect of the exposure to gimatecan (ST1481) and
topotecan on topoisomerase I protein level and enzymatic
activity was investigated. HT1376 and MCR cells were
incubated with equitoxic concentrations (approximately
IC50) of ST1481 or topotecan for 1 hour. The drugs were
then removed from the culture medium and, after 4, 24, and
72 hours, Western blot and topoisomerase I activity assays
Figure 3. Effect of gimatecan (ST1481) or topotecan treatment on topoisomerase I expression of HT1376 cell line. Nuclear protein extract was obtained from cells
treated with ST1481 (0.01 g/ml) or topotecan (1 g/ml) for 1 hour, immediately after treatment (A) or after 4 hours of washout (B), or after 24 hours of washout (C),
or after 72 hours of washout (D). Equal amounts of nuclear protein (3 g) were resolved on 8% SDS polyacrylamide gel, blotted onto nitrocellulose membrane, and
probed with antihuman DNA topoisomerase I monoclonal antibody. The bands of topoisomerase I were visualized using chemiluminescence system. Actin was
used as a control of protein loading.
Figure 4. Effect of gimatecan (ST1481) or topotecan treatment on topoisomerase I expression in MCR cell line. Nuclear protein extract was obtained from cells
treated with ST1481 (0.1 g/ml) or topotecan (1 g/ml) for 1 hour, immediately after treatment (A), or after 4 hours of washout (B), or after 24 hours of washout (C),
or after 72 hours of washout (D). Equal amounts of nuclear protein (3 g) were resolved on 8% SDS polyacrylamide gel, blotted onto nitrocellulose membrane, and
probed with antihuman DNA topoisomerase I monoclonal antibody. The bands of topoisomerase I were visualized using chemiluminescence system. Actin was
used as a control of protein loading.
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of nuclear extracts were performed. The immunoblots dis-
played a decrease in topoisomerase I protein level after
drug treatment. As shown in Figures 3 and 4, ST1481-
treated and topotecan-treated cells revealed a different
pattern of modulation of topoisomerase I level. Topoisomer-
ase I reduction was more marked after exposure to topo-
tecan in both cell lines. A 1-hour treatment with topotecan
strongly reduced the protein level both in HT1376 and MCR
cells, with the reduction being evident also after 4 hours of
incubation of drug-free medium. A complete downregulation
of topoisomerase I was observed 24 and 72 hours after
drug removal. In contrast, when cells were treated with
ST1481, the disappearance of topoisomerase I was slower.
Indeed, the protein was still detected in the nuclear extracts
of HT1376 cells after 72 hours of incubation in drug-free
medium. We therefore evaluated the effect of ST1481 and
topotecan on topoisomerase I enzyme activity (Figures 5
and 6). The decreased topoisomerase I level in topotecan-
treated cells resulted in a dramatic reduction of enzyme
activity. Indeed, no activity was found in the nuclear extracts
of HT1376 and MCR cells treated with topotecan after 24
and 72 hours of incubation in drug-free medium. The re-
duction of the enzymatic activity was greater in topotecan-
treated than in ST1481-treated cells. The nuclear extract
from MCR cells revealed the presence of enzymatic activity
4 and 24 hours after drug removal, whereas nuclear extract
from HT1376 cells was still active after 72 hours of incuba-
tion in ST1481-free medium. Thus, the results of the en-
zyme activity assays revealed a good correlation with the
analysis of protein levels.
Expression of the 20S Proteasome Subunit a2 and Effect
of a Proteasome Inhibitor
Camptothecin-induced downregulation of topoisomerase
I has been ascribed to degradation of the enzyme by a
ubiquitin/26S proteasome pathway [12]. The different re-
sponses of HT1376 and MCR cells to ST1481 did not reflect
a different expression of the proteasome itself (Figure 7).
Indeed, in spite of an increased downregulation of topoiso-
merase I in treated MCR cells, the level of proteasome was
somewhat lower than in HT1376 cells. In an attempt to
provide indirect evidence that, in bladder carcinoma cells,
the downregulation of topoisomerase I reflects degradation
of the enzyme by a ubiquitin/26S proteasome pathway, we
studied the effect of the proteasome inhibitor, PS341, on
Figure 5.Modulation of topoisomerase I activity by gimatecan (ST1481) or topotecan in HT1376 cell line. Cells were treated with ST1481 (0.01 g/ml) or topotecan
(1 g/ml) for 1 hour. After 4 hours (A), 24 hours (B), and 72 hours (C) of incubation in drug-free medium, nuclear protein was extracted from 5  106 cells as
indicated in Material and Methods section. Supercoiled plasmid DNA (375 ng) was unwinded by 30-minute incubation at 37jC with adequately diluted nuclear
protein extract and resolved on 1% agarose gel. Arrow: Bands of supercoiled plasmid DNA. Bracket: Bands of plasmid DNA unwinded by topoisomerase I. Figures
are representatives of at least three experiments.
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the antiproliferative activity of both camptothecins (Figure 8).
Only a moderate potentiation of camptothecin activity was
observed in MCR cells, when cells were exposed to subtoxic
concentration of PS341 for 72 hours after 1-hour exposure to
the camptothecin. No potentiation was observed in HT1376
cells. The lack of synergistic effects of camptothecins and
proteasome inhibitors suggests that the downregulation
of topoisomerase I is not directly related to downstream
events involving the proteasome-mediated degradation of
the enzyme.
Effect on Topoisomerase I Transcription
The effect of exposure to ST1481 and topotecan on
topoisomerase I mRNA level was investigated in HT1376
and MCR cells incubated with 0.01 and 0.1 mg/ml ST1481,
respectively, and with 1 mg/ml topotecan for 1 hour. After
RNA extraction, RT-PCR analysis was performed by using
specific primers. As shown in Figure 9, a similar pattern of
drug-induced topoisomerase I mRNA decrease was ob-
served in both cell lines. However, HT1376 cells were more
sensitive and topotecan induced a greater mRNA reduction
in both cell lines.
Discussion
The bladder carcinoma models used in the present study
are characterized by a slow proliferation rate. Slowly grow-
ing tumors are expected to be relatively resistant to camp-
tothecin treatment. Indeed, HT1376 tumor xenografts
exhibited a marginal responsiveness to topotecan. In con-
trast, the effect of gimatecan was remarkable because,
using the same intermittent treatment schedule, it produced
a significant tumor growth inhibition (93%). This level of
activity was achieved in spite of an apparent cytostatic
response and lack of apoptosis of the HT1376 observed
in vitro. A lack of correlation between an early apoptotic
response and in vivo efficacy of gimatecan has been
already observed in the human prostate carcinoma model
PC3 and has been ascribed to a delayed apoptosis follow-
ing a persistent arrest in G2 [13]. In other cell lines, we have
found that S-phase arrest is associated with a relative
resistance to gimatecan [8]. It is conceivable that the
activation of the S-phase checkpoint reflects a protective
mechanism to prevent the generation of double-strand
breaks rather than a manifestation of the presence of lethal
lesions. Indeed agents that perturb cell progression through
S-phase reduce the effectiveness of camptothecins [14].
Figure 6. Modulation of topoisomerase I activity by gimatecan (ST1481) or topotecan in MCR cell line. Cells were treated with ST1481 (0.1 g/ml) or topotecan
(1 g/ml) for 1 hour. After 4 hours (A), 24 hours (B), and 72 hours (C) of incubation in drug-free medium cells, nuclear protein was extracted from 5  106 cells as
indicated in Materials and Methods section. Supercoiled plasmid DNA (375 ng) was unwinded by 30-minute incubation at 37jC with adequately diluted nuclear
protein extract and resolved on 1% agarose gel. Arrow: Bands of supercoiled plasmid DNA. Bracket: Bands of plasmid DNA unwinded by topoisomerase I. Figures
are representatives of at least three experiments.
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The results of the present work and previous observations
in other cells support our interpretation and could account
for a lack of apoptosis. However, because multiple signals
regulate apoptosis and cell cycle, the cell propensity to
undergo apoptosis may be cell type–specific [15].
The present study also provides evidence of a marked
increase of the antiproliferative and antitumor potency of
gimatecan over topotecan. Previous studies have indicated
a peculiar behavior of gimatecan at cellular and molecular
levels [16]. The lipophilic nature of gimatecan accounts for
the substantially increased cellular accumulation compared
to topotecan [13,17]. In addition, the preferential subcellular
localization of gimatecan in lysosomes could allow the
release of an active lactone form of the drug because the
acidic environment of lysosomes may favor the stabilization
of the closed lactone [18]. In addition to the favorable cellular
pharmacokinetics, gimatecan is a potent inhibitor of top-
oisomerase I and produces a persistent stabilization of the
DNA–enzyme-cleavable complex [11,19]. The present
study may suggest an additional mechanism involved in
antitumor potency and efficacy. Indeed, the available results
obtained in both bladder carcinoma models indicated that
topotecan induced a more marked downregulation of top-
oisomerase I compared to gimatecan. The gimatecan-
induced downregulation was more pronounced in MCR cells
than in HT1376 cells, and may be consistent with the
increased sensitivity of HT1376 to gimatecan. This event
is regarded as an important determinant of sensitivity/resis-
tance of tumor cells to camptothecins and has been ascribed
to a process downstream from the topoisomerase I–DNA-
cleavable complex mediated by ubiquitin/26S proteasome
[12]. Because 26S proteasome inhibitors are expected
to sensitize tumor cells to camptothecins [12], we studied
the effect of PS341 as a specific inhibitor in combination
with both camptothecins. The results indicated a moderate
potentiation of both agents by PS341 only in MCR cells, thus
suggesting the contribution of alternative mechanisms of
topoisomerase I downregulation. The downregulation of top-
oisomerase I, following treatment with topoisomerase
I inhibitors, appears to be a heterogeneous phenome-
non involving upstream and downregulation processes
[12,20,21]. Indeed, we have found an early inhibition
of topoisomerase I transcription induced by both camptothe-
cins. This effect was more pronounced in topotecan-treated
cells. The effects of topotecan and gimatecan on down-
regulation of the enzyme protein in HT1376 paralleled the
differential effect of the two agents at mRNA levels.
This finding and the lack of sensitization by the proteasome
inhibitor PS341 suggest that, in HT1376 cells, the topoisom-
erase I downregulation is primarily the result of the inhibition
of transcription. In contrast, in MCR cells, the downregulation
of topoisomerase I was likely the contribution of drug effects
at both mRNA level and downstream level. Gimatecan
produced a limited effect in both events, resulting in
a reduced downregulation of the target. A plausible expla-
nation of the differential effect of the two camptothecins
Figure 7.Western blot analysis of the proteasome in HT1376 and MCR cells.
The relative expression level of the proteasome subunit a2 was normalized
with respect to actin.
Figure 8. Interaction between gimatecan (ST1481) or topotecan and PS341.
Antiproliferative activity of the combination was determined after 1-hour
exposure to the camptothecin and 72-hour exposure to PS341 using SRB
assay. Dose– response curves for each camptothecin were determined in the
presence of subtoxic concentrations of PS341 (i.e., 0.001 g/ml; i.e., under
conditions that did not produce antiproliferative effects of the proteasome
inhibitor). The combination index was calculated according to the method of
Skehan et al. [9].
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could be related to the increased specificity of gimatecan
for the target enzyme. Indeed, as a consequence of the
inhibitory potency [19], a lower number of drug molecules
could be required to produce topoisomerase I–mediated
DNA damage. Because the inhibition of transcription is
expected to involve several genes, the increased potency
and specificity of gimatecan for the target enzyme could
spare aspecific cellular effects caused by arrest of transcrip-
tion. In addition, the stability of the covalent DNA–enzyme
complex [19] could result in a slower 26S proteasome–
mediated degradation of topoisomerase I. Regardless of
the mechanisms involved, the evidence of a limited impact
of gimatecan on the topoisomerase I levels provides novel
insights into the cellular basis of the drug efficacy be-
cause the modulation of the target by camptothecins may
affect the drug sensitivity/resistance of tumor cells. Indeed,
camptothecin-induced downregulation of topoisomerase I
has been proposed as a resistance mechanism [12]. The
differential effect of gimatecan and topotecan on topoiso-
merase I level represents a potential therapeutic advantage
because optimal treatment with camptothecins requires pro-
tracted administration.
In conclusion, this study provides evidence that gimatecan
was effective also against a slowly growing tumor and very
potent both in vitro and in vivo, in spite of an apparent
cytostatic effect and lack of apoptosis. Multiple events, in-
cluding antiangiogenic effects [22], and the persistence of
gimatecan effects may contribute to the potency and anti-
tumor efficacy of the drug [16]. The present study, showing a
mild downregulation of topoisomerase I level and a mild
inhibition of transcription by gimatecan, may suggest that
these events could contribute to drug antitumor specificity
because the inhibition of gene expression is expected to
cause severe toxicity [21].
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